Review highlights the potential of AI models in predicting cardiovascular disease risks but emphasizes the need for independent external validation to ensure their clinical applicability.
Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock
A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic
June 6, 2024